Australian Commission on Safety and Quality in Health Care, A. (2011). Patientcentred Care: Improving Quality and Safety Through Partnerships With Patients and Consumers. Sydney: ACSQHC.
Australian Government, D. o. S. S. (2015). National FrameWork for Action on Dementia 2015–2019. Canberra, Australia: Australian Government, Department of Social Services.
Azermai, M., Petrovic, M., Elseviers, M. M., Bourgeois, J., Van Bortel, L. M. and Vander Stichele, R. H. (2012). Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Research Reviews, 11, 78–86.
et al. (2008). A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine/Public Library of Science, 5, e76.
et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151–157.
et al. (2016). Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the well-being and health for people with dementia (WHELD) program. American Journal of Psychiatry, 173, 252–262.
Ballard, C. and Waite, J. (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Systematic Review, CD003476.
Barca, M. L., Engedal, K., Laks, J. and Selbaek, G. (2010). A 12 months follow-up study of depression among nursing-home patients in Norway. Journal of Affective Disorders, 120, 141–148.
Briesacher, B. A., Tjia, J., Field, T., Peterson, D. and Gurwitz, J. H. (2013). Antipsychotic use among nursing home residents. Journal of the American Medical Association, 309, 440–442.
et al. (2001). Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. International Journal of Geriatric Psychiatry, 16, 504–512.
et al. (2003). A randomised placebo controlled trial of risperidone for the treatment of agitation and psychosis of dementia. Journal of Clinical Psychiatry, 64, 134–143.
Brooker, D. J.
et al. (2016). FITS into practice: translating research into practice in reducing the use of anti-psychotic medication for people with dementia living in care homes. Aging and Mental Health, 20, 709–718.
et al. (2015). Non-pharmacological interventions as a best practice strategy in people with dementia living in nursing homes. A systematic review. European Geriatric Medicine, 6, 134–150.
et al. (2014). PerCEN: a cluster randomized controlled trial of person-centered residential care and environment for people with dementia. International Psychogeriatrics, 26, 1147–1160.
et al. (2015). PerCEN trial participant perspectives on the implementation and outcomes of person-centered dementia care and environments. International Psychogeriatrics, 27, 2045–2057.
et al. (2009). Caring for aged dementia care resident study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurology, 8, 317–325.
Cohen-Mansfield, J., Marx, M. S. and Rosenthal, A. S. (1989). A description of agitation in a nursing home. Journal of Gerontology, 44, M77–84.
Cornegé-Blokland, E., Kleijer, B. C., Hertogh, C. M. P. M. and van Marum, R. J. (2012). Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: a survey in Dutch nursing homes among physicians, nurses, and family caregivers. Journal of the American Medical Directors Association, 13, 80.e81–80.e86.
Cummings, J. L. (1997). The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology, 48, S10–16.
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.
Devanand, D. P.
et al. (2012). Relapse risk after discontinuation of risperidone in Alzheimer's disease. New England Journal of Medicine, 367, 1497–1507.
Edvardsson, D., Winblad, B. and Sandman, P. O. (2008). Person-centred care of people with severe Alzheimer's disease: current status and ways forward. Lancet Neurology, 7, 362–367.
Ervin, K., Cross, M. and Koschel, A. (2014). Barriers to managing behavioural and psychological symptoms of dementia: staff perceptions. Collegian, 21, 201–207.
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
et al. (2006). Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. British Medical Journal, 332, 756–761.
Hilmer, S. N. and Gnjidic, D. (2013). Rethinking psychotropics in nursing homes. Medical Journal of Australia, 198, 77.
Hinton, L., Franz, C., Reddy, G., Flores, Y., Kravitz, R. and Barker, J. (2007). Practice constraints, behavioral problems, and dementia care: primary care physicians’ perspectives. Journal of General Internal Medicine, 22, 1487–1492.
Jorm, A. F.
et al. (1995). The psychogeriatric assessment scales: a multi-dimensional alternative to categorical diagnoses of dementia and depression in the elderly. Psychological Medicine, 25, 447–460.
Kada, S., Nygaard, H. A., Mukesh, B. N. and Geitung, J. T. (2009). Staff attitudes towards institutionalised dementia residents. Journal of Clinical Nursing, 18, 2383–2392.
Kane, J. M. and Correll, C. U. (2010). Past and present progress in the pharmacologic treatment of schizophrenia. The Journal of Clinical Psychiatry, 71, 1115–1124.
Katz, I. R., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J. and Brecher, M. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone study group. Journal of Clinical Psychiatry, 60, 107–115.
Lawton, M. P. and Brody, E. M. (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. The Gerontologist, 9, 179–186.
Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W. and Davis, J. M. (2014). Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophrenia Bulletin, 40, 314–326.
Logsdon, R. G., Gibbons, L. E., McCurry, S. M. and Teri, L. (1999). Quality of life in Alzheimer's disease: patient and caregiver reports. Journal of Mental Health and Aging, 5, 21–32.
Maguire, A., Hughes, C., Cardwell, C. and O'Reilly, D. (2013). Psychotropic medications and the transition into care: a national data linkage study. Journal of the American Geriatrics Society, 61, 215–221.
et al. (2010). Developing person-centred practice: nursing outcomes arising from changes to the care environment in residential settings for older people. International Journal of Older People Nursing, 5, 93–107.
National Institute for Health and Care Excellence. (2006). Dementia: supporting people with dementia and their carers in health and social care. Clinical guideline. https://www.nice.org.uk/guidance/cg42
O'Connor, D. W., Griffith, J. and McSweeney, K. (2010). Changes to psychotropic medications in the six months after admission to nursing homes in Melbourne, Australia. International Psychogeriatrics, 22, 1149–1153.
Peisah, C., Chan, D. K., McKay, R., Kurrle, S. E. and Reutens, S. G. (2011). Practical guidelines for the acute emergency sedation of the severely agitated older patient. Internal Medicine Journal, 41, 651–657.
Pruchno, R. A., Kleban, M. H. and Resch, N. L. (1988). Psychometric assessment of the Multidimensional Observation Scale for Elderly Subjects (MOSES). Journal of Gerontology, 43, P164–169.
Royal Australian and New Zealand College of Psychiatrists, R. (2011). The use of antipsychotics in residential aged care. Clinical Recommendations developed by the RANZCP Faculty of Psychiatry of Old Age (New Zealand).
Scott, I. A.
et al. (2015). Reducing inappropriate polypharmacy: the process of deprescribing. Journal of the American Medical Association Internal Medicine, 175, 827–834.
Snowdon, J., Galanos, D. and Vaswani, D. (2011). Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. International Psychogeriatrics, 23, 1520–1525.
Stein-Parbury, J., Chenoweth, L., Jeon, Y. H., Brodaty, H., Haas, M. and Norman, R. (2012). Implementing person-centered care in residential dementia care. Clinical Gerontologist, 35, 404–424.
Storey, J. E., Rowland, J. T. J., Conforti, D. A. and Dickson, H. G. (2004). The Rowland Universal Dementia Assessment Scale (RUDAS): a multicultural cognitive assessment scale. International Psychogeriatrics, 16, 13–31.
Westbury, J. (2014). Quality use of Psychotropic Medications in RACFs. Canberra, Australia: Pharmaceutical Society of Australia Ltd.
Whitney, J., Close, J. C., Lord, S. R. and Jackson, S. H. (2012). Identification of high risk fallers among older people living in residential care facilities: a simple screen based on easily collectable measures. Archives of Gerontology and Geriatrics, 55, 690–695.
Zaudig, M. (2000). A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Drug Safety, 23, 183–195.